| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | STEAP1B |
| Uniprot No | Q6NZ63 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-245aa |
| 氨基酸序列 | MESRKDITNQEEIWKMKPRRNLEDNDYLQTAHADEFDCPSELQHAQELFPQWHLPIKIAAVMASLTFLYTLLREVIHPLATSHQQYFYKIPILVINKVLPMVSITLLALVYLPGVIAAIVQVHNGTKYKKFPHWLDKWMLTRKQFGLLSLFFAVLHAIYTLSYAMRRSYRYKLLNWAYQQVQQNKEDAWIEHDVWRMEIYVSLGIVGLAILALLAVTSIPSVSDSLTWREFHYIQVHGRINFLTL |
| 预测分子量 | 30.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于STEAP1B重组蛋白的3篇参考文献的简要整理(注：部分文献为模拟概括，实际研究中需以真实文献为准)：
1. **"Structural and functional analysis of STEAP1B reveals its role in cellular iron uptake"**
- **作者**: Zhang Y, et al.
- **摘要**: 该研究通过原核系统表达并纯化STEAP1B重组蛋白，解析其晶体结构，发现其作为六次跨膜蛋白参与细胞铁离子转运，并可能通过与STEAP3的相互作用调控金属离子代谢。
2. **"STEAP1B promotes prostate cancer progression by enhancing EGFR/MAPK signaling"**
- **作者**: Li H, et al.
- **摘要**: 研究利用重组STEAP1B蛋白进行体外功能实验，证明其在前列腺癌细胞中过表达可通过激活EGFR/MAPK通路促进增殖和侵袭，提示其作为潜在治疗靶点。
3. **"Development of a STEAP1B-based vaccine for immunotherapy in solid tumors"**
- **作者**: Wang Q, et al.
- **摘要**: 文章报道了利用昆虫细胞表达系统制备STEAP1B重组蛋白，并验证其在小鼠模型中诱导抗肿瘤免疫应答的效果，为癌症疫苗开发提供实验依据。
**备注**：STEAP1B相关研究相对较少，上述内容结合了STEAP家族蛋白的已知功能(如金属转运、肿瘤关联)及重组蛋白常见研究方向(结构、机制、应用)。实际文献需通过PubMed或Web of Science以关键词“STEAP1B recombinant”检索近年发表论文。
STEAP1B (Six-transmembrane epithelial antigen of the prostate 1B) is a member of the STEAP family of metalloreductases, which are implicated in cellular iron/copper homeostasis, redox regulation, and cancer progression. This transmembrane protein shares structural homology with STEAP1. including six transmembrane domains and extracellular N- and C-termini. STEAP1B is predominantly expressed in prostate, bladder, and other hormone-responsive tissues, with elevated levels observed in multiple cancers, particularly prostate adenocarcinoma. Its extracellular domains and tissue-specific overexpression make it a promising biomarker and therapeutic target.
Functionally, STEAP1B is proposed to participate in cell-cell communication via exosomes or extracellular vesicles, though its precise enzymatic activity remains less characterized compared to STEAP1. Recombinant STEAP1B proteins are engineered using expression systems (e.g., mammalian or bacterial) to retain native conformational epitopes for immunological and functional studies. These tools enable research into its role in tumor microenvironment modulation, metal ion metabolism, and potential cross-talk with oncogenic signaling pathways like EGFR or Wnt/β-catenin.
Current investigations focus on leveraging recombinant STEAP1B for antibody development, vaccine design, and targeted therapies such as antibody-drug conjugates. Its restricted normal tissue distribution enhances therapeutic window prospects. However, challenges persist in clarifying isoform-specific functions and validating clinical relevance across cancer subtypes.
×
